

中文題目：表皮生長因子受體 L858R 突變的肺腺癌患者使用 Ocimertinib 治療引發心包膜積水
英文題目：Ocimertinib related pericardial effusion in a case of pulmonary adenocarcinoma with
detection of epidermal growth factor receptor: L858R mutation

作者：李佩娟¹, 賴俊良¹

服務單位：¹ 大林慈濟醫院內科部; ² 大林慈濟醫院內科部胸腔科

Background: Pericardial effusion is a rare but serious adverse effect in patients with tyrosine kinase inhibitor of epidermal growth factor receptor(EGFR). Here, we reported a patient with EGFR: L858R mutant lung adenocarcinoma who developed pericardial effusion after ocimertinib treatment.

Method: A 48-year-old male patient was diagnosed as adenocarcinoma of lung, RUL, cT4N3M1c, cstage IVB, EGFR: L858R under osimertinib use. He presented with progressive dyspnea for one week.

Results: Echocardiogram showed large amount of pericardial effusion. Osimertinib was discontinued and the patient received pericardial window surgery. No malignant cells were found in the pericardium. Systemic steroid was prescribed for ocimertinib related pericardial effusion. Symptom gradually improved.

Conclusion: Cardio-toxicity such as pericardial effusion should be monitored while using osimertinib .